Home > Neurology > ECF 2020 > ECF Round-Up Articles > Characteristics of a population-based MS cohort treated with DMDs

Characteristics of a population-based MS cohort treated with DMDs

Conference
ECF 2020
A Canadian population study identified that almost 1 in 5 multiple sclerosis (MS) patients were ≥50 years old at the time of their first disease-modifying drug (DMD). Additionally, about the same percentage has at least some comorbidity. As these individuals are typically excluded from clinical trials, the study illustrates there is a need to understand the harms and benefits of DMD use in understudied groups. The efficacy of DMDs is typically established via short clinical trials with a follow-up of 2-3 years, in highly select and motivated groups of MS patients. In clinical practice, DMDs are used for many years in a much more diverse patient population. Relatively little is known about the use of DMDs for MS in the population-based universal healthcare setting. The current study from Canada described the characteristics of a cohort of 10,418 MS patients exposed to their first DMD in the real-world setting; 74% were women [1]. At study entry, 17% ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on